Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Corporate Update (October 2019)
6 slides from Therapeuticsmd's corporate update, Oct 15, 2019
Slide 1: Investor Update: Building a Premier Women's Health Portfolio
Investor Update October 15, 2019 Building a Premier Women’s Health Portfolio 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than
Slide 3: September Launch Metrics: IMVEXXY
September Launch Metrics IMVEXXY Launch Metrics Total paid scripts1 ~44,900 (September 1-30, 2019) Total patients ~95,300 (since launch through September 30, 2019) Total prescribers2 ~15,700 (since launch through September 30, 2019) 1 Total prescription data is based on IQVIA prescriber level data p
Slide 4: Launch Results Remain Strong
Launch Results Remain Strong Imvexxy TRx Launch Comparison 70,000 10.0% 60,000 8.5% 52,600 8.0% 7.9% 47,900 50,000 6.0% 43,200 6.0% 40,000 44,900 4.0% 4.0% 28,700 37,500 30,000 2.0% 1.9% 21,000 28,100 20,000 0.0% 19,800 8,800 10,000 -2.0% 8,400 0 Month Month Month Month Month Month Month Month Month
Slide 5: Continued Strong Patient Adherence
Continued Strong Patient Adherence IMVEXXY Patient Adherence1,2 Maximum Average # Fills Month Initial Allowable Fills for Those Prescription Filled Given the Month Patients of Initial Fill Sep 2019 1 Fill 1 Fill IMVEXXY: 4.0 fills/yr3 (through Sept) Aug 2019 1.8 Fills 2 Fills • Vaginal creams: avera
Slide 6: September Launch Metrics: BIJUVA
September Launch Metrics BIJUVA Launch Metrics Total paid scripts dispensed to patients1 (since launch through September 30, 2019) ~20,400 Total paid scripts (September 1-30, 2019) ~6,200 Total patients (since launch through September 30, 2019) ~9,100 Total prescribers2 (since launch through Septemb